Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment.
However, immune-related adverse effects (irAEs) have also increased with the exponential …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Novel neoadjuvant therapy regimens are warranted for oral squamous cell carcinoma
(OSCC). In this phase I trial (NCT04393506), 20 patients with locally advanced resectable …

Immune-checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4),
programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) have …

Purpose In 2016, ASCO published a guideline to assist in clinical decision making in
metastatic pancreatic cancer for initial assessment after diagnosis, first-and second-line …

Background Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1
(PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related …

Oncology has recently undergone a revolutionary change with widespread adoption of
immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against …

Incapacitated immune system is a characteristic hallmark of solid tumors. Immune system
within a tumor undergoes an imbalance in cellular dispersion and functionality. Effector cells …

Renal cell carcinomas vary considerably in their tumor biology and disease course, which is
reflected in the range of treatment paradigms in localized and metastatic renal cell …

Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer
(NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy …